Experimental combo aims to boost stem cell transplant for rare blood cancers
NCT ID NCT02512497
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tested whether adding the drug romidepsin before and after a stem cell transplant could help control T-cell cancers like lymphoma and leukemia. Twenty-three patients received romidepsin along with standard chemotherapy, followed by a donor stem cell transplant. The main goals were to find the safest dose and see if the approach helped patients engraft and survive at least 30 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Romidepsin (also known as Istodax)
What this could lead to
If this works, it could point toward a safer and more effective way to use stem cell transplants for T-cell cancers, potentially improving long-term control of the disease.
What could go wrong
This is a very early phase 1 trial with only 23 participants, so the results are preliminary. The combination may cause serious side effects, and it is not yet known if it truly improves outcomes compared to standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS T CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Ohio State University Cancer Center
Columbus, Ohio, 43210, United States